IRVINE, Calif.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced the completion of patient enrollment in the Company’s initial Phase 3 registration trial (“Mercury 1”) of RoclatanTM (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, a novel once-daily eye drop being tested for its ability to lower intraocular pressure (IOP)
A new study has shown that Ebola survivors may be at risk of severe vision loss or blindness weeks after being declared virus-free. The research is being presented at the 2016 Annual Meeting of the Association for Research in Vision and Ophthalmology t…
Building on existing evidence, vision researchers have found that limiting exposure to blue light after sunset increases the quality and length of sleep. The research is being presented at the 2016 Annual Meeting of the Association for Research in Visi…
Status: Completed,
Condition Summary: Graves’ Ophthalmopathy
Ab interno canaloplasty reduced IOP and medication use in patients with primary open-angle glaucoma, according to a press release from Ellex Medical Lasers.Ellex reported results of a case series review on ab interno canaloplasty (ABiC), an update of ab externo canaloplasty performed with the iTrack 250-µm microcatheter. ABiC does not require a tensioning suture to maintain IOP reduction and can be performed alone or in combination with cataract surgery, the release said.
Two studies from the University of Miami Miller School of Medicine shed light on physiological and genetic factors associated with uveal melanoma (UM). Reuters Health Information